Clinical usefulness of different lipid measures for prediction of coronary heart disease in type 2 diabetes: A report from the Swedish National Diabetes Register

Diabetes Care

Volumn 34, Issue 9, 2011, Pages 2095-2100

  Eliasson, Björn ^a   Cederholm, Jan ^b   Eeg Olofsson, Katarina ^a   Svensson, Anne Marie ^c   Zethelius, Björn ^b   Gudbjörnsdottir, Soffia ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c Center of Registers in Region Vastra Gotaland   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET THERAPY; DISEASE ASSOCIATION; FATALITY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PREDICTION; RISK FACTOR; SWEDEN; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CORONARY ARTERY DISEASE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SWEDEN; TRIGLYCERIDES;

EID: 84855911551     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-0209     Document Type: Article

References (25)

1. Grundy SM, Cleeman JI, Merz CN, et al.; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239 (Pubitemid 38924592)
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
3. American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care 2011;34(Suppl. 1):S11-S61
4. De Backer G, Ambrosioni E, Borch-Johnsen K, et al.; Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-1610 (Pubitemid 37012194)
5. Rydén L, Standl E, Bartnik M, et al.; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes and cardiovascular diseases. Eur Heart J 2007;28:88-136 (Pubitemid 46137814)
6. Gudbjörnsdottir S, Cederholm J, Nilsson PM, Eliasson B; Steering Committee of the Swedish National Diabetes Register. The National Diabetes Register in Sweden: an implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. Diabetes Care 2003;26:1270-1276 (Pubitemid 36929284)
7. Eliasson B, Cederholm J, Nilsson P, Gudbjörnsdóttir S; Steering Committee of the Swedish National Diabetes Register. The gap between guidelines and reality: type 2 diabetes in a National Diabetes Register 1996-2003. Diabet Med 2005;22:1420-1426 (Pubitemid 41391321)
8. Eeg-Olofsson K, Cederholm J, Nilsson PM, et al. Glycemic control and cardiovascular disease in 7,454 patients with type 1 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Diabetes Care 2010;33:1640-1646
9. Eeg-Olofsson K, Cederholm J, Nilsson PM, et al. New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). J Intern Med 2010;268:471-482
10. Cederholm J, Gudbjörnsdottir S, Eliasson B, Zethelius B, Eeg-Olofsson K, Nilsson PM; NDR. Systolic blood pressure and risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish national diabetes register. J Hypertens 2010;28:2026-2035
11. Hoelzel W, Weykamp C, Jeppsson JO, et al.; IFCC Working Group on HbA1c Standardization. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 2004;50:166-174 (Pubitemid 38125714)
12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
13. Merlo J, Lindblad U, Pessah-Rasmussen H, et al. Comparison of different procedures to identify probable cases of myocardial infarction and stroke in two Swedish prospective cohort studies using local and national routine registers. Eur J Epidemiol 2000;16:235-243 (Pubitemid 30351427)
14. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994;90:583-612
15. Holman RR, Coleman RL, Shine BSF, Stevens RJ. Non-HDL cholesterol is less informative than the total-to-HDL cholesterol ratio in predicting cardiovascular risk in type 2 diabetes. Diabetes Care 2005;28:1796-1797 (Pubitemid 40923097)
16. Taskinen MR. Type 2 diabetes as a lipid disorder. Curr Mol Med 2005;5:297-308
17. Sniderman AD. Apolipoprotein B, diabetes and medical consensus. Ann Clin Biochem 2010;47:2-3
18. Taskinen MR, Barter PJ, Ehnholm C, et al.; FIELD study investigators. Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. Diabetologia 2010;53:1846-1855
19. Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007;298:776-785 (Pubitemid 47263160)
20. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010;53:1270-1287
21. Razani B, Chakravarthy MV, Semenkovich CF. Insulin resistance and atherosclerosis. Endocrinol Metab Clin North Am 2008;37:603-621
22. Tsuchihashi K, Hikita N, Hase M, et al. Role of hyperinsulinemia in atherosclerotic coronary arterial disease: studies of semi-quantitative coronary angiography. Intern Med 1999;38:691-697
23. Wassink AM, van der Graaf Y, Olijhoek JK, Visseren FL; SMART Study Group. Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 2008;29:213-223
24. Takeuchi H, Saitoh S, Takagi S, et al. Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program-Adult Treatment Panel III to Japanese men - the Tanno and Sobetsu Study. Hypertens Res 2005;28:203-208 (Pubitemid 40812603)
25. Eliasson B, Svensson A-M, Miftaraj M, et al. Clinical use and effectiveness of lipid lowering therapies in diabetes mellitus - an observational study from the Swedish national diabetes register. PLoS ONE 2011;6:e18744